<DOC>
	<DOCNO>NCT00818519</DOCNO>
	<brief_summary>The purpose study evaluate efficacy safety YAZ ( drospirenone 3 mg / ethinylestradiol 20 Âµg ) comparison placebo female patient moderate acne vulgaris 6 treatment cycle .</brief_summary>
	<brief_title>GA YAZ ACNE China Phase III</brief_title>
	<detailed_description />
	<mesh_term>Acne Vulgaris</mesh_term>
	<mesh_term>Drospirenone</mesh_term>
	<mesh_term>Contraceptives , Oral</mesh_term>
	<mesh_term>Ethinyl Estradiol</mesh_term>
	<mesh_term>Contraceptive Agents</mesh_term>
	<criteria>Women age 1445 year &gt; 1 year postmenarche moderate acne vulgaris know contraindication combine oral contraceptive Otherwise healthy , except presence moderate acne Smokers maximum age 30 ( inclusive ) inclusion Pregnancy , lactation ( less three menstrual cycle since delivery , abortion , lactation start treatment ) Obesity ( Body Mass Index &gt; 30 kg/m2 ) Hypersensitivity ingredient study drug Any disease condition may worsen hormonal treatment</criteria>
	<gender>Female</gender>
	<minimum_age>14 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>Moderate Acne Vulgaris</keyword>
	<keyword>Oral contraceptive</keyword>
	<keyword>Female</keyword>
</DOC>